Skip to main content
Top
Published in: CEN Case Reports 2/2017

01-11-2017 | Case report

McArdle disease: a “pediatric” disorder presenting in an adult with acute kidney injury

Authors: Xixi Zhao, Angela Li, Madhu Soni, Michael J. Muriello, Carolyn H. Jones, William L. Whittier

Published in: CEN Case Reports | Issue 2/2017

Login to get access

Abstract

Rhabdomyolysis is characterized by the acute breakdown of skeletal muscle, resulting in the release of muscle cell contents, subsequent myoglobinuria, and in severe cases, acute renal failure. A number of etiologies have been identified in acute rhabdomyolysis, in which drugs and trauma account for the majority of cases. One etiological category that is commonly overlooked in the adult population is an underlying genetic defect. This may be challenging to diagnose due to its rarity in the adult demographic and the marked heterogeneity, often requiring a high level of clinical suspicion before investigation is pursued. Once diagnosed, however, appropriate steps can be taken to reduce future episodes of rhabdomyolysis, further renal injury, and other systemic complications. Here, we report a case of an adult patient presenting with acute rhabdomyolysis secondary to McArdle disease, a genetic disease causing defective glycogenolysis. The case highlights the importance of recognizing the potential of undiagnosed “pediatric” disorders in adulthood and particularly for underlying genetic causes of rhabdomyolysis.
Literature
1.
go back to reference Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine. 1982;61(3):141–52.CrossRef Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine. 1982;61(3):141–52.CrossRef
2.
go back to reference Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med. 1988;148(7):1553–7.CrossRef Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med. 1988;148(7):1553–7.CrossRef
3.
go back to reference Elsayed EF, Reilly RF. Rhabdomyolysis: a review, with emphasis on the pediatric population. Pediatr Nephrol. 2010;25(1):7–18.CrossRef Elsayed EF, Reilly RF. Rhabdomyolysis: a review, with emphasis on the pediatric population. Pediatr Nephrol. 2010;25(1):7–18.CrossRef
4.
go back to reference Rubio JC, Lucia A, Fernández-Cadenas I, et al. Novel mutation in the PYGM gene resulting in McArdle disease. Arch Neurol. 2006;63(12):1782–4.CrossRef Rubio JC, Lucia A, Fernández-Cadenas I, et al. Novel mutation in the PYGM gene resulting in McArdle disease. Arch Neurol. 2006;63(12):1782–4.CrossRef
5.
go back to reference Pearson CM, Rimer DG, Mommaerts WFHM. A metabolic myopathy due to absence of muscle phosphorylase. Am J Med. 1961;30(4):502–17.CrossRef Pearson CM, Rimer DG, Mommaerts WFHM. A metabolic myopathy due to absence of muscle phosphorylase. Am J Med. 1961;30(4):502–17.CrossRef
6.
go back to reference Lucia A, Nogales-Gadea G, Pérez M, et al. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008;4(10):568–77.CrossRef Lucia A, Nogales-Gadea G, Pérez M, et al. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008;4(10):568–77.CrossRef
7.
go back to reference Quinlivan R, Jungbluth H. Myopathic causes of exercise intolerance with rhabdomyolysis. Dev Med Child Neurol. 2012;54(10):886–91.CrossRef Quinlivan R, Jungbluth H. Myopathic causes of exercise intolerance with rhabdomyolysis. Dev Med Child Neurol. 2012;54(10):886–91.CrossRef
8.
go back to reference Thuillier L, Rostane H, Droin V, et al. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency. Hum Mutat. 2003;21(5):493–501.CrossRef Thuillier L, Rostane H, Droin V, et al. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency. Hum Mutat. 2003;21(5):493–501.CrossRef
9.
go back to reference Laforêt P, Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord. 2010;20(11):693–700.CrossRef Laforêt P, Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord. 2010;20(11):693–700.CrossRef
10.
go back to reference Pfeffer G, Chinnery PF. Diagnosis and treatment of mitochondrial myopathies. Ann Med. 2013;45(1):4–16.CrossRef Pfeffer G, Chinnery PF. Diagnosis and treatment of mitochondrial myopathies. Ann Med. 2013;45(1):4–16.CrossRef
11.
go back to reference Scalco RS, Gardiner AR, Pitceathly RDS. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis. 2015;10(1):51.CrossRef Scalco RS, Gardiner AR, Pitceathly RDS. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis. 2015;10(1):51.CrossRef
12.
go back to reference Bosch X, Poch E, Grau JM, et al. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.CrossRef Bosch X, Poch E, Grau JM, et al. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.CrossRef
13.
go back to reference Scalco RS, Snoeck M, Quinlivan R, et al. Exertional rhabdomyolysis: physiological response or manifestation of an underlying myopathy? BMJ Open Sport Exerc Med. 2016;2:e000151.CrossRef Scalco RS, Snoeck M, Quinlivan R, et al. Exertional rhabdomyolysis: physiological response or manifestation of an underlying myopathy? BMJ Open Sport Exerc Med. 2016;2:e000151.CrossRef
14.
go back to reference Galea M, Jelacin N, Bramham K, et al. Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose. Br J Anaesth. 2007;98(2):213–5.CrossRef Galea M, Jelacin N, Bramham K, et al. Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose. Br J Anaesth. 2007;98(2):213–5.CrossRef
15.
go back to reference Ursini F, Succurro E, Grembiale A, et al. Acute rhabdomyolysis during treatment with amisulpride and metformin. Eur J Clin Pharmacol. 2010;66(3):321–2.CrossRef Ursini F, Succurro E, Grembiale A, et al. Acute rhabdomyolysis during treatment with amisulpride and metformin. Eur J Clin Pharmacol. 2010;66(3):321–2.CrossRef
16.
go back to reference Kao DP, Kohrt HE, Kugler K. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med. 2008;25(10):1229–30.CrossRef Kao DP, Kohrt HE, Kugler K. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med. 2008;25(10):1229–30.CrossRef
17.
go back to reference Yokayama M, Izumiya Y, Yoshizawa M, et al. Acute rhabdomyolysis associated with troglitazone. Diabetes Care. 2000;23:421–2.CrossRef Yokayama M, Izumiya Y, Yoshizawa M, et al. Acute rhabdomyolysis associated with troglitazone. Diabetes Care. 2000;23:421–2.CrossRef
18.
go back to reference Ledl M, Hohenecker J, Francesconi C. Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate, and rosiglitazone. Diabetologia. 2005;48:1996–8.CrossRef Ledl M, Hohenecker J, Francesconi C. Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate, and rosiglitazone. Diabetologia. 2005;48:1996–8.CrossRef
19.
go back to reference Slim R, Salem CB, Zamy M, et al. Pioglitazone-induced acute rhabdomyolysis. Diabetes Care. 2009;7:e84.CrossRef Slim R, Salem CB, Zamy M, et al. Pioglitazone-induced acute rhabdomyolysis. Diabetes Care. 2009;7:e84.CrossRef
20.
go back to reference Koro CE, Sowell MO, Stender M, et al. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case control analysis. Clin Ther. 2008;30(3):535–42.CrossRef Koro CE, Sowell MO, Stender M, et al. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case control analysis. Clin Ther. 2008;30(3):535–42.CrossRef
21.
go back to reference Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013;44(2):360–6.CrossRef Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013;44(2):360–6.CrossRef
22.
go back to reference Bhanushali GK, Jain G, Fatima H, et al. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. 2012;8(4):523–6.CrossRef Bhanushali GK, Jain G, Fatima H, et al. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. 2012;8(4):523–6.CrossRef
23.
go back to reference Durand D, Delgado LL, de la Parra-Pellot DM, et al. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin Schizophr Relat Psychoses. 2013;8(4):205–8.CrossRef Durand D, Delgado LL, de la Parra-Pellot DM, et al. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin Schizophr Relat Psychoses. 2013;8(4):205–8.CrossRef
24.
go back to reference Paul ABM, Simms L, Paul AE, et al. Not safe for consumption: synthetic cannabinoids causing fatal acute rhabdomyolysis in two young men. Int J Case Rep Images. 2016;7:431–5.CrossRef Paul ABM, Simms L, Paul AE, et al. Not safe for consumption: synthetic cannabinoids causing fatal acute rhabdomyolysis in two young men. Int J Case Rep Images. 2016;7:431–5.CrossRef
25.
go back to reference Zhao A, Tan M, Maung A, et al. Rhabdomyolysis and acute kidney injury requiring dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids. Case Rep Nephrol. 2015;2015:235982.PubMedPubMedCentral Zhao A, Tan M, Maung A, et al. Rhabdomyolysis and acute kidney injury requiring dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids. Case Rep Nephrol. 2015;2015:235982.PubMedPubMedCentral
26.
go back to reference Dubowitz V, et al. Muscle biopsy: a practical approach. Amsterdam: Elsevier Health Sciences; 2013. p. 89. Dubowitz V, et al. Muscle biopsy: a practical approach. Amsterdam: Elsevier Health Sciences; 2013. p. 89.
Metadata
Title
McArdle disease: a “pediatric” disorder presenting in an adult with acute kidney injury
Authors
Xixi Zhao
Angela Li
Madhu Soni
Michael J. Muriello
Carolyn H. Jones
William L. Whittier
Publication date
01-11-2017
Publisher
Springer Singapore
Published in
CEN Case Reports / Issue 2/2017
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-017-0265-2

Other articles of this Issue 2/2017

CEN Case Reports 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.